oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

3 ( 1 )

2020 ( 7 )

2019 ( 64 )

2018 ( 181 )

Custom range...

Search Results: 1 - 10 of 13535 matches for " Polycystic ovary syndrome "
All listed articles are free for downloading (OA Articles)
Page 1 /13535
Display every page Item
Serum Adiponectin levels in Different Phenotypes of Polycystic Ovary Syndrome  [PDF]
Carolina Fux Otta, Paula Szafryk de Mereshian, Raquel Kaplan, Gabriel Santino Iraci, Silvia Ojeda, José Ochoa, Andrés Albrecht, Natalia Filipone, Marta Fiol de Cuneo
Open Journal of Endocrine and Metabolic Diseases (OJEMD) , 2012, DOI: 10.4236/ojemd.2012.24019
Abstract: Objectives: to evaluate and compare serum adiponectin levels in different phenotypes of polycystic ovary syndrome (PCOS) and to investigate their correlation with endocrine and metabolic parameters. Material and methods: we studied 5 groups of patients: A (n = 20): H (hyperandrogenism) + O (oligoanovulation) + P (polycystic ovary) [classic phenotype]; B (n = 17): H + O [classic phenotype but normal ovaries]; C (n = 15): H + P [Ovulatory phenotype]; D (n = 17): O + P [Normoandrogenic phenotype]; and E (n = 16) control group. Body mass index, waist circumference, waist/hip ratio, blood pressure and hirsutism were evaluated. Serum concentrations of adiponectin, insulin, Creactive protein, SHBG, androgens and lipids were measured. Oral glucose tolerance test was performed. Results: there were no differences between the groups in terms of age and BMI. Total cholesterol, LDL-C and triglyceride levels were higher in phenotype A than in C (P < 0.05); HDL-C was slightly lower in phenotype D compared to E (P = 0.03). HOMA-IR, insulin and glucose/insulin ratio were significantly higher in phenotypes A and D vs C and E (P < 0.05). Serum adiponectin levels were lower in phenotype A (11.6 ± 8 ug/mL) than in the rest of the groups (B: 12.5 ± 8 ug/mL; C: 20.5 ± 8 ug/mL; D: 17.4 ± 4 ug/mL; E: 20 ± 6 ug/mL). This diference reached statistical significance when comparing group A with groups C and E (P < 0.05). Adiponectin levels were significant and negatively correlated with total testosterone, free androgen index, androstenedione, DHEAS, 17-hydroxyprogesterone, LH/FSH, insulin, HOMA-IR, Creactive protein, LDL-C, triglycerides, and waist/hip ratio. A positive correlation was found with glucose/insulin ratio and HDL-C (P < 0.05). Conclusions: adiponectin serum concentrations vary according to the phenotypic expression of PCOS. Our results suggest that adiponectin could be used as a biochemical marker to identify phenotypes at increased metabolic risk.
Influence of Thioctic Acid on the Hyperinsulinemia and Ovarian Volume in Female Patients with Polycystic Ovary Syndrome  [PDF]
L. A. Ivanova
Open Journal of Endocrine and Metabolic Diseases (OJEMD) , 2015, DOI: 10.4236/ojemd.2015.54005
Abstract: 45 female patients with polycystic ovary syndrome took thioctic acid (Thioctacid-HR), 600 mg (n = 25) or high protein diet (n = 20). Fast insulin and glucose stimulus insulin were investigated before and after 3 months taken treatment. The use of thioctic acid, 600 mg is a new effective pathogenetics therapy of polycystic ovary syndrome on influence of hyperinsulinemia, HOMA-IR index and ovary volume in female patients with polycystic ovary syndrome.
The Effects of Plasma Homocysteine in PCOS Women: A Review  [PDF]
Pranita Maharjan, Peng Dan Hong
Open Journal of Obstetrics and Gynecology (OJOG) , 2018, DOI: 10.4236/ojog.2018.81005
Abstract: Homocysteine is an intermediate substance formed during the breakdown of the amino acid methionine and may undergo remethylation to methionine or trans-sulfuration to cystathionine or cysteine. The metabolism occurs via two pathways: remethylation to methionine, which requires folate and vitamin B12; and transsulfuration to cystathionine, which requires pyridoxal-5’-phosphate. The disturbances in the metabolic pathways lead to the accumulation of Hcy, either by insufficient transsulfuration (through CBS mutations or vitamin B6 deficiency) or by a blockage of remethylation. In the latter case, folate or vitamin B12 deficiency may be involved, as well as MTHFR. High levels of Hcy induce sustained injury of arterial endothelial cells, proliferation of arterial smooth muscle cells and enhance activity of key participants in vascular inflammation, atherogenesis, and vulnerability of the established atherosclerotic plaque. Hyperhomocysteinemia has become the topic of interest in recent years. It has been highly associated with increased risk for cardiovascular disorders, such as, atherosclerosis, thromboembolism and dyslipidemia. Women with PCOS show constellation of metabolic syndromes. Obesity, hyperandrogenemia and type 2 diabetes mellitus is the hallmark of PCOS which later becomes the risk factors for cardiovascular disease. Various studies had revealed the presence of increased Hcy level in PCOS women which may or may not be associated with other biochemical parameters. Intense treatment for PCOS can influence homocysteine levels.
Physicians’ Attitude toward the Use of Metformin Prior to Clomiphene Citrate in Infertile Women with PCOS in Saudi Arabia  [PDF]
Moayad Humaid, Eman Shaldoom, Adel Habhab, Huda Habib, Ayman Oraif
Open Journal of Obstetrics and Gynecology (OJOG) , 2018, DOI: 10.4236/ojog.2018.81007
Abstract: The goal of this study is to assess the different approaches gynecologists take while treating women with PCOS related infertility. Methodology: This is a quantitative cross-sectional study that involves 46 specialists and consultants from all over the kingdom of Saudi Arabia. The sample size was calculated based on the number of consultants and specialists members in the Saudi Obstetrical & Gynecology society “SOGS”, we could not find any statistics on how many Ob/Gyne doctors we have in Saudi Arabia. The paper is approved by the Unit of Biomedical Ethics, King Abdulaziz University. The research team prepared an online survey of 13 questions, sent to all Consultants and Specialists in the “SOGS” during the year of 2016. The SPSS was used for the analysis. Conclusion: There is no significant difference between the different approaches of the first line of management. Comparing between Metformin and Clomiphene Citrate, Thirty Seven percent of participants preferred to start by a combination while 32% preferred to start with the former and 30.4% with the latter. Most of the doctors preferred to use Metformin for the Obese patients 76.1%, a lower percentage prefers to use it with Overweight patients 54.3%.
SINDROME DE OVARIO POLIQUISTICO: PRESENTACION CLINICA, BIOQUIMICA Y ULTRASONOGRAFICA
Pérez C.,Jorge; Méndez R.,María J.; Fuhrer F.,Juan; Marquez N.,Juan; Cumsille,Miguel A.; Fuhrer C.,Juan;
Revista chilena de obstetricia y ginecología , 2003, DOI: 10.4067/S0717-75262003000600003
Abstract: a retrospective study is made in the endocrinology unit of the gynecology dept. of the san josé hospital. 115 records of patients with polycystic ovary syndrome are reviewed who consulted in the unit between 1996 and 2002. the prevalence is determined and a demographic, hormonal and ultrasonographic profile was done on these patients. it emphasizes the presence of a high percentage of obesity that reached 63% and insulin-resistant of the order of 76%. the lh was elevated in 47% of our patients and the total testosterone and free testosterone showed a low percentage of alteration (11 and 27% respectively). ultrasonography shows patterns characteristic of pcos (increased volume and suggestive morphology) in around 70% of the cases. these findings induce to us to prioritize the study in these patients on the basis of lh and to insulin-resistance instead of the androgen levels. from the metabolic point of view there was a low percentage of arterial hypertension and diabetes mellitus ii (2.6 and 6.1% respectively)
Bases genéticas del síndrome de ovarios poliquísticos
Ovies Carballo,Gisel; Martínez de Sandelices,Alicia; Monteagudo Pe?a,Gilda; Sardi?as Díaz,Irelys;
Revista Cubana de Endocrinolog?-a , 2011,
Abstract: the syndrome of polycystic ovaries is the endocrine disorder involving more the reproductive sphere of the woman in fertile age, its causes are unknown with accuracy, but most of experts coincide in propose that it is a multifactor entity where the genetic factor more and more have a great significance. in past years, it has been possible to identify some genes involved in the pathogenic processes of this syndrome and among the more important are included those codifying for enzymes of the steroidogenesis, for the insulin receptor and other hormones related to the insulin action, as well as the gonadotropins and its receptors, features that are the aim of present review.
Treatment options for polycystic ovary syndrome
Ahmed Badawy, Abubaker Elnashar
International Journal of Women's Health , 2011, DOI: http://dx.doi.org/10.2147/IJWH.S11304
Abstract: eatment options for polycystic ovary syndrome Review (19109) Total Article Views Authors: Ahmed Badawy, Abubaker Elnashar Published Date February 2011 Volume 2011:3 Pages 25 - 35 DOI: http://dx.doi.org/10.2147/IJWH.S11304 Ahmed Badawy1 Abubaker Elnashar2 1Department of Obstetrics and Gynecology, Mansoura University, Mansoura, Egypt; 2Department of Obstetrics and Gynecology, Benha University, Benha, Egypt Abstract: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women. The clinical manifestation of PCOS varies from a mild menstrual disorder to severe disturbance of reproductive and metabolic functions. Management of women with PCOS depends on the symptoms. These could be ovulatory dysfunction-related infertility, menstrual disorders, or androgen-related symptoms. Weight loss improves the endocrine profile and increases the likelihood of ovulation and pregnancy. Normalization of menstrual cycles and ovulation could occur with modest weight loss as little as 5% of the initial weight. The treatment of obesity includes modifications in lifestyle (diet and exercise) and medical and surgical treatment. In PCOS, anovulation relates to low follicle-stimulating hormone concentrations and the arrest of antral follicle growth in the final stages of maturation. This can be treated with medications such as clomiphene citrate, tamoxifen, aromatase inhibitors, metformin, glucocorticoids, or gonadotropins or surgically by laparoscopic ovarian drilling. In vitro fertilization will remain the last option to achieve pregnancy when others fail. Chronic anovulation over a long period of time is also associated with an increased risk of endometrial hyperplasia and carcinoma, which should be seriously investigated and treated. There are androgenic symptoms that will vary from patient to patient, such as hirsutism, acne, and/or alopecia. These are troublesome presentations to the patients and require adequate treatment. Alternative medicine has been emerging as one of the commonly practiced medicines for different health problems, including PCOS. This review underlines the contribution to the treatment of different symptoms.
Enhancement of Sister Chromatid Exchanges (SCEs) in Peripheral Blood Lymphocytes of Women with Polycystic Ovary Syndrome (PCOS) in Vitro  [PDF]
Evagelia Dafa, Maria Kontou, Tzegiaver B. Mantratzi, Emmanouel N. Kontomanolis, Nikoletta G. Koutlaki, Vasilios A. Liberis, Theodore S. Lialiaris
Open Journal of Obstetrics and Gynecology (OJOG) , 2015, DOI: 10.4236/ojog.2015.57055
Abstract: The aim of the present study was to determine the level of underlying DNA damage in females with PCOS. Twenty-two women with PCOS and twenty-two healthy controls were included in this study. Patients were further categorized into three phenotypic subgroups: Subgroup A, oligo/anovulation (ANOV) and polycystic ovaries (PCO); Subgroup B, hyperandrogenism (HA) as a main characteristic (HA + ANOV or HA + PCO); Subgroup C, all three conditions present (HA + ANOV + PCO). The frequency of sister chromatid exchanges (SCEs) was used as an index of cytogenetic damage. Proliferation rate index (PRI), mitotic index (MI), average generation time (AGT) and population doubling time (PDT) were also evaluated. A significant (p < 0.01) increase in SCE levels along with a significant (p < 0.01) reduction in PRIs and MIs were observed in women with PCOS compared with healthy subjects. Additionally, subgroup C demonstrated statistically significant differences compared with others, while subgroup A had similar results with healthy females. Our results suggest that females with PCOS show increased chromosomal instability in peripheral lymphocytes and a consequent inability of the cells to promote their own mitotic cycle. A positive correlation between DNA damage and PCOS phenotypes is also reported.
Polycystic Ovary Syndrome (PCOS) and Fertility  [PDF]
Guilherme Barbosa, Larissa Bianca Paiva Cunha de Sá, Denise Rosso Tenório Wanderley Rocha, Alberto Krayyem Arbex
Open Journal of Endocrine and Metabolic Diseases (OJEMD) , 2016, DOI: 10.4236/ojemd.2016.61008
Abstract: The polycystic ovary syndrome (PCOS) is defined as a combination of hyperandrogenism (hirsutism and acne) and anovulation (oligomenorrhea, infertility, and dysfunctional uterine bleeding), with or without the presence of polycystic ovaries on ultrasound. It represents the main endocrine disorder in the reproductive age, affecting 6% - 15% of women in menacme. It is the most common cause of infertility due to anovulation, and the main source of female infertility. When in the presence of a menstrual disorder, the diagnosis of PCOS is reached in 30% - 40% of patients with primary or secondary amenorrhoea and in 80% of patients with oligomenorrhea. PCOS should be diagnosed and treated early in adolescence due to reproductive, metabolic and oncological complications which may be associated with it. Treatment options include drugs, diet and lifestyle improvement.
Polycystic Ovary Syndrome and the Role of Metformin in Ovulation Induction  [PDF]
Fabiana Fraga, Gabriel Azeredo César Salgado Romeiro, Larissa Bianca Paiva Cunha de Sá, Alberto Krayyem Arbex
Health (Health) , 2018, DOI: 10.4236/health.2018.105045
Abstract: The Polycystic Ovary Syndrome (PCOS) is frequently associated with comorbidities such as obesity, reduced glucose tolerance, hypertension, macrovascular disease and dyslipidemia. The Metabolic syndrome occurs in 30% of women with PCOS. Metformin has increasingly been used in this therapy due to its effects in reducing insulin resistance. Treatment of PCOS aims to reduce the symptoms of hyperandrogenism, regularize the menstrual cycle, reduce metabolic abnormalities, and lower the risk of type 2 diabetes mellitus and of cardiovascular disease. Additionally it is important to prevent hyperplasia and endometrial cancer, and to offer contraception to those who do not wish pregnancy, and to help to induce ovulation to those who do. The effectiveness of metformin in this treatment is assessed in the light of the current best evidence.
Page 1 /13535
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.